CAMP and hepatocellular carcinoma: This implies that (1) 1,25(OH)2D3 treatment might increase the hCAP18/LL-37 level in HCC, and (2) the lower expression of hCAP18/LL-37 in HCC may be associated with a severe deficiency of vitamin D in HCC patients [29].